On the afternoon of May 24, 2023, Shanghai Institute of Biomedical Technology (hereinafter referred to as Shanghai Institute of Health Research) and Chengdu Jinshi Technology Co., LTD. (hereinafter referred to as Jinshi Technology) held a cooperation signing and joint laboratory licensing ceremony in Shanghai.  Zheng Huajun, deputy director of the Institute of Immunization, and responsible comrades of relevant competent departments witnessed together.

At the ceremony, Liu Haifeng, Party secretary and vice president of Shanghai Health Research Institute, said: Gene sequencing technology has a wide range of application value in precision diagnosis and treatment, biomedicine, environmental monitoring, food safety and other fields, and the two sides can jointly promote the research and development and application of gene testing technology. Secretary Liu sent a message that the two sides can achieve 1+1>2 through complementary advantages, jointly promote the rapid development of domestic nanopore sequencing technology, and make gene testing better serve the society.

Dr. Su Yunpeng, CEO of Jinshi Technology, said: Set up a joint laboratory with Shanghai Institute of Health and Research to jointly develop the application of our nanopore synthesis and sequencing platform with independent intellectual property rights in microbial genome, human genome, metagenomic sequencing and other fields, and develop automated database construction technology and sequencing data analysis methods suitable for the platform to form products that meet clinical, inspection and quarantine and other market demands. Jointly promote the progress of gene sequencing technology and the popularization of applications in various fields.

In the end, the two sides agreed: Based on the single molecule nanopore sequencer products that are now the independent intellectual property rights of science and technology, relying on the scientific research capabilities and professional technical level of Shanghai Institute of Health Research in the directions of pathogenic biology, reproductive health, precision diagnosis and treatment, we will carry out research on the construction of nanopore sequencing database technology, automated data analysis methods and the development of clinical application products, and promote the rapid development of gene sequencing applications.